CHGA and cancer: By capturing viable CTCs, this platform can be extended to analyze other secretome markers in real time such as chromogranin A and cancer-specific proteases and cytokines, thereby allowing functional profiling and identification of phenotypic groups contributing to tumor heterogeneity.